Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license ...

Q3 2025 Earnings Call Transcript November 12, 2025Snail, Inc. Class A Common Stock misses on earnings expectations.

While FDA reviews PMA application for the upcoming Perimeter B-Series (Company continues to anticipate Agency's decision in H1-2026) , commercial market ...